Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IXO Therapeutics - a new biotechnology company aimed at researching/developing novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases, was launched on 13 December 2010.
Subscribe to our email newsletter
IXO Therapeutics is a start-up from the Natural Environment Research Council (NERC) and will focus on developing intellectual property (IP) derived from both NERC and the University of Oxford.
The company will develop recombinant protein products that will treat inflammation and diseases that affect the body’s immune system, and these proteins will be derived from natural sources.
The company’s portfolio, which is based on the work of professor Pat Nuttall’s group at NERC’s Centre for Ecology & Hydrology, in collaboration with research groups at the University of Oxford, includes a novel dendritic cell modulator, an LTB4 inhibitor and IXO LTB4 inhibitor.
Nuttall said the launch of IXO today is an important step forward as the research is now at a transitional stage.
"IXO expects to develop and produce a number of anti-inflammatory compounds that will target diseases such as rheumatoid arthritis and psoriasis – conditions that are in urgent need of new clinical approaches," Nuttall said.